Rationale: Remote ischaemic conditioning, applied in the prehospital setting and continued in-hospital, may improve functional outcome in patients with acute ischaemic stroke and intracerebral haemorrhage. Aims: To evaluate whether combined remote ischaemic per-and postconditioning can improve long-term functional outcome in acute ischaemic stroke and intracerebral haemorrhage patients. Methods and design: Danish multicentre, prospective, randomised, patient-assessor blinded, sham-controlled study. Adult patients with a putative stroke identified prehospital with symptom duration <4 h, who are independent in daily activities will be randomised 1:1 to remote ischaemic conditioning or Sham-remote ischaemic conditioning. The treatment protocol will be five cycles, each consisting of 5 min with a blood pressure cuff inflation and 5 min with a deflated cuff placed on the upper extremity. The cuff pressure for remote ischaemic conditioning will be 200 mmHg-285 mmHg according to the individual systolic blood pressure and 20 mmHg sham-remote ischaemic conditioning during inflation. The study is approved as an acute study and consent is waived in the acute phase. Sample size estimation: For a 7% increased odds for a beneficial shift on the modified Rankin Scale at a significance level of 5% and power of 90%, 1000 patients with a target diagnosis of acute ischaemic stroke and intracerebral haemorrhage and a total of 1500 patients with a prehospital presumed stroke will be included. Study outcomes: The primary outcome will be the modified Rankin Scale score measured at three-month follow-up (analysed using ordinal logistic regression). ClinicalTrials.gov Identifier: NCT03481777.
Rationale
Intravenous alteplase (IV tPA) and endovascular treatment (EVT) are approved acute reperfusion treatments for acute ischaemic stroke (AIS) to be started as soon as possible. [1] [2] [3] Infarct progression can continue for days following a stroke in some patients, and failure of the collateral flow is a critical factor determining infarct growth. 4 The pre-eminent therapeutic aim is therefore to restore blood flow, improve collateral perfusion and prevent ischaemic brain injury. 5 On the other hand, in intracerebral haemorrhage (ICH), the pathophysiological mechanism is an eruption of blood into the brain parenchyma, causing tissue destruction with mass effect on adjacent brain tissues. Haematoma expansion as well as inflammatory pathways that are activated lead to further tissue damage, oedema and penumbral hypoperfusion. 6 Novel therapeutics and neuroprotective strategies that can be started ultra-early after symptom onset are urgently needed to reduce disability in both AIS and ICH. 7, 8 Ischaemic conditioning is one of the most potent activators of endogenous protective mechanisms against ischaemic injury. [9] [10] [11] Remote ischaemic conditioning (RIC) can be applied as repeated short-lasting ischaemia in tissue remote to the brain that results in protection against subsequent long-lasting ischaemic brain injury. 12 It can be applied prior to or during a prolonged ischaemic event as remote ischaemic preconditioning and perconditioning, respectively, or immediately after reperfusion as remote ischaemic postconditioning. 13 RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-min cycles of limb ischaemia alternating with 5 min of reperfusion. RIC activates several protective mechanisms, through humoral and neuronal pathways. 14 Results from a recent proof-of-concept study at our institution indicated that RIC applied during ambulance transportation (perconditioning) as an adjunctive therapy to in-hospital IV tPA increases brain tissue survival after one month, although no effect on acute infarct growth or clinical outcome was found. 15 No detrimental effect on haematoma expansion was found in patients with ICH, and emerging preclinical data indicate a significant increased haematoma reabsorption rate and an improved outcome after RIC-treated ICH. 16 To-date, no serious adverse events have been documented in RIC. RIC is a feasible, non-pharmacologic and safe non-invasive treatment without significant discomfort that can be initiated prehospital worldwide. 8, 15, [17] [18] [19] [20] The aim of the current study is to evaluate whether combined remote ischaemic per-and postconditioning can improve long-term functional outcome in AIS and ICH patients.
Methods and design

Design
REmote iSchemic conditioning In patients with acute STroke (RESIST) is a multicentre, prospective, randomised, patient-assessor blinded, sham-controlled study.
The study is approved as an acute study (consent is waived in the acute phase) by the Danish regional research ethics committees (ID:1-10-72-97-17), Danish
Medicines Agency (ID:2017114177, EUDAMED: CIV-17-11-022324) and the Danish Data Protection Agency (ID: 1-16-02- [16] [17] [18] .
The trial will be conducted in accordance with good clinical practice guidelines (ICH-GCP), declaration of Helsinki (as revised in 2013) and is monitored by regional Good Clinical Practice units. The trial protocol is in accordance with SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. 21 The ClinicalTrials.gov Identifier is: NCT03481777.
Patient population
Patients with a prehospital putative stroke from participating stroke centres in Denmark will be recruited.
All Danish stroke centres and their prehospital regions will be invited to participate (currently three initiated stroke centres and one planned). Inclusion and exclusion criteria are listed in Figure 1 and baseline assessments and study procedures in Table 1 .
Randomisation
A prehospital stroke screening and severity assessment (PreSS) will be performed in the ambulance by paramedics or emergency medical technicians. The PreSS consists of the Cincinnati Prehospital Stroke Scale with an additional opportunity to report other neurological symptoms (e.g. ataxia, sensory disturbances and visual field loss) and PASS (Prehospital Acute Stroke Severity Scale). 22, 23 The patient will be randomised to standard treatment with RIC or sham-RIC by the oncall neurologist at the receiving stroke centre using a randomised block design with random sized blocks. Lists of randomisation keys are computer generated and provided by a secure website. Patients are stratified by the receiving stroke centre, age (strata of age: 18 to 65, 66 to 80 and >80 years) and prehospital stroke severity (strata of PreSS: 1-2, 3-4 and 5-6 present symptoms/deficits).
Intervention
RIC and sham-RIC devices were developed in collaboration with Aarhus University, Faculty of Biomedical Engineering (Aarhus, Denmark) and produced by Seagull Healthcare (Slagelse, Denmark). Both RIC and sham devices are programmed for five cycles (50 min), each consisting of five minutes of cuff inflation followed by 5 min with a deflated cuff. For the RIC-device, default cuff pressure will be 200 mmHg; however, if the initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure to ensure complete arterial occlusion (maximum cuff pressure 285 mmHg). Cuff-pressure variability below 10 mmHg is accepted. The sham-RIC device will only inflate to a pressure of 20 mmHg. Every ambulance and helicopter in the participating Danish regions will be equipped with two investigational devices (RIC and Sham-RIC). The initial RIC/sham-RIC treatment protocol will be applied in the acute prehospital phase.
In cases of transport time under 50 min, the RIC/ sham-RIC protocol continues during the initial assessment at the stroke centre until the 50-min treatment time has been achieved. The cuff will whenever possible by default be placed on the non-paretic upper extremity and if monosymptomatic aphasia on the left upper extremity.
At 6 h after completion of the first RIC/sham-RIC protocol, an additional series of RIC/sham-RIC will be performed (postconditioning) for all patients with a confirmed stroke diagnosis.
For patients with a stroke diagnosis admitted to Aarhus University Hospital, ischaemic postconditioning will continue twice daily (8 am and 8 pm) for seven days. Ischaemic postconditioning will continue at home/rehabilitation if the patient is discharged before day 7.
Patients in both groups will receive standard care, which includes acute reperfusion therapy (IV tPA (alteplase, 0.9 mg/kg, 10% as bolus) and/or EVT (stent retrievers and/or direct aspiration first-pass technique), according to national and international guidelines.
Study outcomes
Primary outcome
The primary outcome will be the three months modified Rankin Scale (mRS) score. The mRS score will be determined by either face-to-face assessment or based on structured telephone interviews performed by two different assessors who are blinded to the allocated intervention. If disagreement occurs, the patient will be contacted by a blinded third and final assessor. The structured telephone interview is based upon a validated Danish translation of the 'slightly revised simplified modified Rankin Scale questionnaire'. 24 Every possible effort will be made to assess the outcome in patients who are unable to participate in the interview. The outcome will then be assessed by contact to a named relative or the general practitioner.
Secondary outcomes
There are three categories of secondary outcomes: clinical (I), neuroimaging (II) and biomarkers (III). For the clinical outcomes (I): analysis on early neurological improvement (NIHSS and PreSS), three months functional outcome (mRS) and Major Adverse Cardiac and Cerebral Events and Mortality will be performed. Neuroimaging (II): Acute (24-h) infarct growth (AIS), 24-h haematoma expansion and seven days haematoma reabsorption rate.
As for the biomarker endpoints (III): exploratory analysis on biomarkers for identifying RIC responders and in general as stroke diagnostics and prognostication tools will be performed. Selected secondary endpoints with planned statistical analysis are listed in Table 2 .
Data monitoring and safety committee
An independent data monitoring and safety committee will meet at regular intervals during the trial and ensure the safety of enrolled patients. They will assist and advise the Trial Steering Committee, assessing the validity and credibility of the trial and ensure that risk/benefit ratio for participants remains acceptable. The Data monitoring and safety committee (DMSC) have complete access to all trial-related data and will meet at least once every 12 months. The committee will make recommendations to the sponsor regarding study modification, continuation or termination. Predefined special attention will be given to the distribution of serious adverse events, three months functional outcome, mortality, acute haematoma growth in ICH (24 h) and acute neurological deterioration (24 h).
Sample size estimates
The treatment effect of RIC on long-term functional outcome is unknown. We have assumed a small but clinical significant neuroprotective effect corresponding to a 7% increased odds for a beneficial shift on the mRS. The sample size calculation was based on a simulation-based approach to the analysis of statistical power when ordinal logistic regression analysis is performed (significance level of 5%).
The statistical power was simulated at different hypothetical sample sizes (on the target population ranging from 200 to 1900) with 2000 simulation-runs Table 2 . Secondary endpoints.
Clinical (I)
Neuroimaging (II) mRS at three months by subgroups of: AIS (General ordinal logistic regression, significance level 5%) performed at each step. Unpublished data on IV-tPA and/or EVT-treated AIS and ICH patients from our institution were used (not shown).
24-h haematoma growth in ICH patients
Based on our previous trial experience with prehospital RIC, we estimate that a sample of 1000 subjects with target diagnosis (AIS and ICH) will be feasible to include during the study period (1500 with a prehospital putative stroke). Including 1000 patients with a target diagnosis provides sufficient power (90%) at a significance-level of 5% to detect RIC treatment effects of the estimated 7% (Table 3 ). We estimate that 85% of confirmed stroke patients will be AIS and the remaining 15% will be ICH. Reperfusion therapy rates in AIS patients is estimated to be 50%
Statistical analysis (Primary endpoint)
The primary endpoint will be three months mRS score in the population fulfilling the in-hospital inclusion criteria (target population, Figure 1 ). The primary trial analysis will be performed on the target population which consists of prehospital randomised patients with an in-hospital diagnosis of AIS (including TIA with a DWI lesion) or ICH regardless of adherence to investigational treatment (modified Intention-To-Treat). 25 The main analysis of the primary study endpoint will be performed using the entire range ('shift analysis') of the mRS (General ordinal logistic regression, with a random effect on the stratification groups as outlined in the section on randomisation).
All patients randomised in RESIST will have a focal neurological deficit at enrolment (documented on the prehospital stroke score). The presence or absence of specific focal neurological symptoms will be assessed again after 24 h using the same score as prerandomisation (PreSS) in all randomised patients (PreSS 24 h/at discharge). The primary safety analysis will be made on the entire randomised population using the difference in prehospital stroke score (PreSS) to document change in neurological deficits between prerandomisation and 24 h/discharge (General ordinal logistic regression). Furthermore, vascular events and mortality in the 12-month follow-up period will be analysed for all randomised subjects.
If RIC is associated with ultra-early treatment effect and reduced symptom severity (in the ambulances), this could affect the in-hospital indication for IV-tPA and/ or EVT (in the case of rapid improvement of symptoms or mild symptoms). Because of this, a supplementary analysis using general ordinal logistic regression, adjusted for possible imbalances in reperfusion treatments (IV-tPA and EVT) between treatment arms will be made.
Study organisation and funding
The sponsor of the trial is Aarhus University and Aarhus University Hospital. The study is funded by TrygFonden, Novo Nordisk Foundation, Manufacturer Vilhelm Pedersen and Wife's foundation, Aase Ejnar Danielsen's Foundation and Aarhus University. Neither the funding sources, nor the device manufactures, have had any influence on study design, data collection, analysis or interpretation, nor the decision to publish or the preparation, review and approval of the manuscript. The investigators have no financial interest in the investigational devices.
Current status of the trial
The study started recruitment in March 2018 and the estimated completion date is December 2022. As of 23 September 2019: 409 patients have been recruited. 
Discussion
In the current trial, we use a combination of remote ischaemic perconditioning (prehospital) and postconditioning (in-hospital) to achieve possible synergistic effects and improve long-term recovery. [26] [27] [28] The primary endpoint for this trial will be functional outcome at three months (mRS) reflecting both possible acute and long-term effects associated with remote ischaemic per-and postconditioning. Treatment is started in the early prehospital phase in patients with a presumed stroke. To prevent an obvious dilution of sample size, the primary efficacy (mRS) endpoint will be analysed on the target population with documented acute vascular lesions (AIS and ICH). For the safety endpoints, the analyses will be based on the entire randomised sample. This approach has been done in a recent comparative study and is considered reasonable given the excellent safety profile of RIC. 15, [17] [18] [19] [20] 25 Several important lessons have been learned from the first RIC pilot study performed at our institution: Automatic devices will be used (sham-controlled), enabling the treatment to continue in-hospital and during rehabilitation/at home. Treatment compliance will be documented electronically on each device.
In our previous study, we found a possible early prehospital treatment effect (before administration of reperfusion treatment) and irrespective of recanalisation status. 15 Furthermore, we found no indication of safety concerns in patients with ICH treated with RIC in prehospital field. Based on this, we have simplified the inclusion criteria to reflect the population of acute stroke patients presenting in the prehospital phase, not limiting it to AIS patients who receive reperfusion therapy.
Summary and conclusion
RESIST is a multicentre, prospective, randomised, patient-assessor blinded, sham-controlled study investigating whether RIC applied in the acute prehospital phase and continued in-hospital improves functional outcome in patients with AIS and ICH. RIC is feasible, safe and promising neuroprotective treatment that has first-aid potential worldwide. Enrolment started in 2018 and is expected to run until the end of 2022.
